
## Jesper Jensen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8532256/publications.pdf Version: 2024-02-01



IFCDED IENICEN

#	Article	IF	CITATIONS
1	Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction. JAMA Cardiology, 2021, 6, 836.	6.1	95
2	Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial. Lancet Diabetes and Endocrinology,the, 2021, 9, 106-116.	11.4	80
3	Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trial. American Heart Journal, 2020, 228, 47-56.	2.7	61
4	Effect of Empagliflozin on Hemodynamics in Patients WithÂHeartÂFailure and Reduced Ejection Fraction. Journal of the American College of Cardiology, 2020, 76, 2740-2751.	2.8	57
5	Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF). Trials, 2019, 20, 374.	1.6	35
6	Effect of Empagliflozin on Blood Volume Redistribution in Patients With Chronic Heart Failure and Reduced Ejection Fraction: An Analysis From the Empire HF Randomized Clinical Trial. Circulation: Heart Failure, 2022, 15, .	3.9	17
7	Prevalence of heart failure and the diagnostic value of MRâ€proANP in outpatients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 736-740.	4.4	16
8	The effect of empagliflozin on growth differentiation factor 15 in patients with heart failure: a randomized controlled trial (Empire HF Biomarker). Cardiovascular Diabetology, 2022, 21, 34.	6.8	10
9	Metabolic Effects of Empagliflozin in Heart Failure: A Randomized, Double-Blind, and Placebo-Controlled Trial (Empire HF Metabolic). Circulation, 2021, 143, 2208-2210.	1.6	8
10	MR-proANP and incident cardiovascular disease in patients with type 2 diabetes with and without heart failure with preserved ejection fraction. Cardiovascular Diabetology, 2020, 19, 180.	6.8	7
11	Hemodynamic Determinants of Activity Measured by Accelerometer in Patients With Stable HeartÂFailure. JACC: Heart Failure, 2021, 9, 824-835.	4.1	4
12	Exercise-induced left bundle branch block – A case report with stress-echocardiographic assessment. Journal of Electrocardiology, 2018, 51, 508-510.	0.9	2
13	Sodiumâ€Glucose Cotransporterâ€2 Inhibitors in Heart Failure with Reduced Ejection Fraction: Current Evidence and Future Perspectives. Basic and Clinical Pharmacology and Toxicology, 2022, , .	2.5	1
14	The Effect of Empagliflozin on Contractile Reserve in Heart Failure: Prespecified Sub-Study of a Randomized, Double-Blind, and Placebo-Controlled Trial. American Heart Journal, 2022, 250, 57-57.	2.7	1
15	Fluid volume regulation in patients with heart failure – Authors' reply. Lancet Diabetes and Endocrinology,the, 2021, 9, 258.	11.4	Ο
16	Response to Patoulias etÂal. letter regarding article "Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trial― American Heart Journal, 2021, 236, 106.	2.7	0
17	Reply. JACC: Heart Failure, 2022, 10, 70-71.	4.1	0
18	Diagnostic and prognostic value of the electrocardiogram in stable outpatients with type 2 diabetes. Scandinavian Cardiovascular Journal, 2022, 56, 256-263.	1.2	0